Cargando…
Advances in cancer research. Volume one hundred and twenty one /
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
San Diego, California :
Academic Press,
2014.
|
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
Tabla de Contenidos:
- Front Cover; Advances in Cancer Research; Copyright; Contents; Contributors; Chapter One: Glial Progenitors as Targets for Transformation in Glioma; 1. Introduction; 2. Glial Cell Lineages; 3. Glioma Subgroups and Cell of Origin; 4. H3F3A Mutations Drive Gliomagenesis in Separate Brain Regions; 4.1. Regulation of DNA methylation by K27 and G34 H3F3A mutations; 4.2. Chromosome and Myc aberrations in H3F3A mutant glioblastoma; 4.3. Delineating the cell of origin for K27 and G34 H3F3A mutant glioblastoma; 5. Gliomagenesis and Mutations in Isocitrate Dehydrogenase Genes.
- 5.1. Models of IDH-mutant gliomas5.2. Glial progenitor-origin for IDH-mutant gliomas; 6. Proneural-to-Mesenchymal Transition in Glioma; 6.1. Mesenchymal phenotype as a function of glioma subgroup; 6.2. Transcriptional master regulators of PMT in glioma; 6.3. Influence of the tumor microenvironment on the mesenchymal phenotype; 7. Relationship Between GSCs and Glial Progenitors; 7.1. Polycomb gene family; 7.2. NOTCH; 7.3. Sonic hedgehog; 7.4. Wingless; 8. Targeted Therapy in Glioma; 8.1. Epidermal growth factor gene family; 8.2. Targeting the proneural subgroup by PDGFR inhibition.
- 8.3. Targeting the mesenchymal phenotype through c-MET inhibition8.4. Treatment-resistance associated with RTK inhibition; 8.4.1. RTK cooperativity; 8.4.2. Redundant activation of PI3K/mTOR; 8.4.3. Feedback loops; 8.4.4. Activation of alternative survival pathways; 8.5. Therapeutic targeting of IDH-mutant gliomas; 9. Concluding Remarks and Future Perspectives; Acknowledgments; References; Further Reading; Chapter Two: Therapeutic Cancer Vaccines; 1. Introduction; 2. Cancer Vaccine Targets; 3. Spectrum of Current Therapeutic Cancer Vaccine Platforms.
- 3.1. An example of optimizing vaccine potency3.2. Vaccine/vaccine combinations; 4. Animal Models to Evaluate Cancer Vaccines: Pros and Cons; 5. Types of Immunotherapy; 5.1. Vaccine therapy and adoptive T-cell transfer: A study in contrasts; 6. The Importance of Antigen Cascade in Vaccine-Mediated Therapeutic Responses; 7. TRICOM-Based Vaccines: Clinical Studies; 8. Prostate Cancer Clinical Trials; 8.1. PSA-TRICOM (PROSTVAC) studies; 8.2. Vaccines and tumor growth rates; 8.3. A case report: Analysis of a prostate cancer patient over an 18-year period; 9. Vaccine Combination Therapies.
- 10. Combination Therapies-Preclinical Studies10.1. Vaccine and radiation synergy; 10.2. Vaccines in combination with chemotherapy; 10.3. Vaccine in combination with small molecule targeted therapies; 10.4. The effect of nonimmune therapeutic interventions on immune cells; 11. Influence of the Tumor Microenvironment and Immunosuppressive Factors; 12. Vaccine Combination Therapies-Clinical Studies; 13. Biomarkers; 14. Vaccine Targets Involved in Tumor Progression and Drug Resistance; 15. Concluding Remarks; References.